

# Ben Davidson

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8776070/ben-davidson-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

252  
papers

8,517  
citations

52  
h-index

78  
g-index

262  
ext. papers

9,561  
ext. citations

4.8  
avg, IF

5.99  
L-index

#	Paper	IF	Citations
252	Comparison of the Idylla <sup>®</sup> MSI assay with the Promega <sup>®</sup> MSI Analysis System and immunohistochemistry on formalin-fixed paraffin-embedded tissue of endometrial carcinoma: results from an international, multicenter study.. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2022</b> , 1	5.1	0
251	Pathophysiology roles and translational opportunities of miRNAs in ovarian cancer <b>2022</b> , 317-322		
250	Comparison of Five Near-Infrared Fluorescent Folate Conjugates in an Ovarian Cancer Model. <i>Molecular Imaging and Biology</i> , <b>2021</b> , 1	3.8	1
249	Peptide vaccine targeting mutated : a potential novel treatment for pseudomyxoma peritonei <b>2021</b> , 9,		1
248	Anti-Angiogenic Treatment in Pseudomyxoma Peritonei-Still a Strong Preclinical Rationale. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
247	Characterizing the Invasive Tumor Front of Aggressive Uterine Adenocarcinoma and Leiomyosarcoma. <i>Frontiers in Cell and Developmental Biology</i> , <b>2021</b> , 9, 670185	5.7	0
246	Update on Sentinel Lymph Node Biopsy in Surgical Staging of Endometrial Carcinoma. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	5
245	Molecular testing on serous effusions. <i>Diagnostic Cytopathology</i> , <b>2021</b> , 49, 640-646	1.4	3
244	ImmunoPeCa trial: Long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis. <i>European Journal of Surgical Oncology</i> , <b>2021</b> , 47, 134-138	3.6	12
243	The phosphatase PTPN1/PTP1B is a candidate marker of better chemotherapy response in metastatic high-grade serous carcinoma. <i>Cytopathology</i> , <b>2021</b> , 32, 161-168	1.3	1
242	Spatial and temporal changes in follicle distribution in the human ovarian cortex. <i>Reproductive BioMedicine Online</i> , <b>2021</b> , 42, 375-383	4	1
241	Repurposing F-FMISO as a PET tracer for translational imaging of nitroreductase-based gene directed enzyme prodrug therapy. <i>Theranostics</i> , <b>2021</b> , 11, 6044-6057	12.1	4
240	Primary uterine ectomesenchymoma harboring a DICER1 mutation: case report with molecular analysis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2021</b> , 479, 419-424	5.1	0
239	Expression of the cancer stem cell marker SSEA1 is associated with poor survival in metastatic high-grade serous carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2020</b> , 477, 677-685	5.1	1
238	CD24-targeted intraoperative fluorescence image-guided surgery leads to improved cytoreduction of ovarian cancer in a preclinical orthotopic surgical model. <i>EBioMedicine</i> , <b>2020</b> , 56, 102783	8.8	11
237	Death domain-associated protein (DAXX) expression is associated with poor survival in metastatic high-grade serous carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2020</b> , 477, 857-864	5.1	2
236	The clinical, morphological, and genetic heterogeneity of endometrial stromal sarcoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2020</b> , 476, 489-490	5.1	0

235	Mutation analysis and genomic imbalances of cells found in effusion fluids from patients with ovarian cancer. <i>Oncology Letters</i> , <b>2020</b> , 20, 2273-2279	2.6	1
234	The Biological Role of the Long Non-coding RNA in Ovarian Carcinoma. <i>Anticancer Research</i> , <b>2020</b> , 40, 6677-6684	2.3	1
233	Expression of Wnt pathway molecules is associated with disease outcome in metastatic high-grade serous carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2020</b> , 477, 249-258	5.1	5
232	MGMT promoter methylation is a rare epigenetic change in malignant effusions. <i>Cytopathology</i> , <b>2020</b> , 31, 12-15	1.3	2
231	Role of the Exosome Secretion Machinery in Ovarian Carcinoma: In Vitro and In Vivo Models. <i>Journal of Oncology</i> , <b>2020</b> , 2020, 1-11	4.5	1
230	The Biological and Clinical Role of the Long Non-Coding RNA LOC642852 in Ovarian Carcinoma. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	3
229	Expression of palladin is associated with disease progression in metastatic high-grade serous carcinoma. <i>Cytopathology</i> , <b>2020</b> , 31, 572-578	1.3	0
228	Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers. <i>Cancer Research</i> , <b>2020</b> , 80, 4514-4526	10.1	19
227	Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer. <i>EBioMedicine</i> , <b>2019</b> , 47, 184-194	8.8	6
226	Biomarkers of drug resistance in ovarian cancer - an update. <i>Expert Review of Molecular Diagnostics</i> , <b>2019</b> , 19, 469-476	3.8	10
225	SOX2 and SOX9 are markers of clinically aggressive disease in metastatic high-grade serous carcinoma. <i>Gynecologic Oncology</i> , <b>2019</b> , 153, 651-660	4.9	19
224	Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response. <i>Journal of Physical Education and Sports Management</i> , <b>2019</b> , 5,	2.8	5
223	Diverse Effects of Lysophosphatidic Acid Receptors on Ovarian Cancer Signaling Pathways. <i>Journal of Oncology</i> , <b>2019</b> , 2019, 7547469	4.5	7
222	Molecular characterization of carcinosarcomas arising in the uterus and ovaries. <i>Oncotarget</i> , <b>2019</b> , 10, 3614-3624	3.3	4
221	Results of multigene panel testing in familial cancer cases without genetic cause demonstrated by single gene testing. <i>Scientific Reports</i> , <b>2019</b> , 9, 18555	4.9	9
220	Soluble AXL is ubiquitously present in malignant serous effusions. <i>Gynecologic Oncology</i> , <b>2019</b> , 152, 408-415	4.5	4
219	Expression and clinical role of the dipeptidyl peptidases DPP8 and DPP9 in ovarian carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2019</b> , 474, 177-185	5.1	7
218	Integrated Molecular Analysis of Undifferentiated Uterine Sarcomas Reveals Clinically Relevant Molecular Subtypes. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 2155-2165	12.9	11

217	Identification of novel cyclin gene fusion transcripts in endometrioid ovarian carcinomas. <i>International Journal of Cancer</i> , <b>2018</b> , 143, 1379-1387	7.5	4
216	Expression and clinical role of long non-coding RNA in high-grade serous carcinoma. <i>Gynecologic Oncology</i> , <b>2018</b> , 148, 559-566	4.9	16
215	Expression of 14-3-3 sigma and eta proteins is unrelated to survival in metastatic high-grade serous carcinoma. <i>Apmis</i> , <b>2018</b> , 126, 309-313	3.4	0
214	Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2018</b> , 473, 463-470	5.1	5
213	The microRNA miR-192/215 family is upregulated in mucinous ovarian carcinomas. <i>Scientific Reports</i> , <b>2018</b> , 8, 11069	4.9	13
212	White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk. <i>Annals of Internal Medicine</i> , <b>2018</b> , 168, 326-334	8	15
211	Circulating tumor cells and cell-free nucleic acids in patients with gynecological malignancies. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2018</b> , 473, 395-403	5.1	1
210	Breast Carcinoma <b>2018</b> , 75-85		
209	Identification of an fusion transcript in low-grade endometrial stromal sarcoma. <i>Oncotarget</i> , <b>2018</b> , 9, 19203-19208	3.3	21
208	Molecular Cytology of Serous Effusions <b>2018</b> , 103-115		1
207	The diagnostic role of PTEN and ARID1A in serous effusions. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2018</b> , 472, 425-432	5.1	5
206	ZC3H7B-BCOR high-grade endometrial stromal sarcomas: a report of 17 cases of a newly defined entity. <i>Modern Pathology</i> , <b>2018</b> , 31, 674-684	9.8	84
205	RNA-sequencing identifies novel GREB1-NCOA2 fusion gene in a uterine sarcoma with the chromosomal translocation t(2;8)(p25;q13). <i>Genes Chromosomes and Cancer</i> , <b>2018</b> , 57, 176-181	5	15
204	The diagnostic role of BAP1 in serous effusions. <i>Human Pathology</i> , <b>2018</b> , 79, 122-126	3.7	14
203	Expression, activation and clinical relevance of CHK1 and CHK2 in metastatic high-grade serous carcinoma. <i>Gynecologic Oncology</i> , <b>2018</b> , 150, 136-142	4.9	3
202	Phospholipase D messenger RNA expression and clinical role in high-grade serous carcinoma. <i>Human Pathology</i> , <b>2017</b> , 62, 115-121	3.7	4
201	Novel Treatment with Intraperitoneal MOC31PE Immunotoxin in Colorectal Peritoneal Metastasis: Results From the ImmunoPeCa Phase 1 Trial. <i>Annals of Surgical Oncology</i> , <b>2017</b> , 24, 1916-1922	3.1	17
200	TGFβ <sub>3</sub> splicing and canonical pathway activation in high-grade serous carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2017</b> , 470, 665-678	5.1	1

199	Epithelial-mesenchymal transition markers in malignant ovarian germ cell tumors. <i>Apmis</i> , <b>2017</b> , 125, 781-786	3.4	5
198	Molecular characteristics of uterine sarcomas. <i>Expert Review of Molecular Diagnostics</i> , <b>2017</b> , 17, 515-522	3.8	13
197	Bilateral ovarian carcinomas differ in the expression of metastasis-related genes. <i>Oncology Letters</i> , <b>2017</b> , 13, 184-190	2.6	3
196	Involvement of DPP9 in gene fusions in serous ovarian carcinoma. <i>BMC Cancer</i> , <b>2017</b> , 17, 642	4.8	13
195	MOC31PE immunotoxin - targeting peritoneal metastasis from epithelial ovarian cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 61800-61809	3.3	7
194	European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery. <i>International Journal of Gynecological Cancer</i> , <b>2017</b> , 27, 1534-1542	3.5	62
193	Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2017</b> , 471, 355-362	5.1	5
192	Reproducibility of measurement of myometrial invasion in endometrial carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2017</b> , 470, 63-68	5.1	8
191	TSAP6 is a novel candidate marker of poor survival in metastatic high-grade serous carcinoma. <i>Human Pathology</i> , <b>2017</b> , 60, 180-187	3.7	8
190	Recurrent fusion transcripts in squamous cell carcinomas of the vulva. <i>Oncotarget</i> , <b>2017</b> , 8, 16843-16850	3.3	2
189	Genomic imbalances are involved in miR-30c and let-7a deregulation in ovarian tumors: implications for HMGA2 expression. <i>Oncotarget</i> , <b>2017</b> , 8, 21554-21560	3.3	11
188	A novel truncated form of in tumors of the ovaries. <i>Oncology Letters</i> , <b>2016</b> , 12, 1559-1563	2.6	7
187	CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells. <i>Human Pathology</i> , <b>2016</b> , 58, 123-127	3.7	19
186	Malignant Nonhematological Effusion Characterization by Flow Cytometry. <i>Acta Cytologica</i> , <b>2016</b> , 60, 365-371	3	10
185	Genomewide copy number analysis of Müllerian adenosarcoma identified chromosomal instability in the aggressive subgroup. <i>Modern Pathology</i> , <b>2016</b> , 29, 1070-82	9.8	23
184	Uterine leiomyosarcoma and endometrial stromal sarcoma have unique miRNA signatures. <i>Gynecologic Oncology</i> , <b>2016</b> , 140, 512-7	4.9	18
183	Recently identified drug resistance biomarkers in ovarian cancer. <i>Expert Review of Molecular Diagnostics</i> , <b>2016</b> , 16, 569-78	3.8	26
182	HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival. <i>Human Pathology</i> , <b>2016</b> , 48, 95-101	3.7	11

181	Ezrin Is Associated with Disease Progression in Ovarian Carcinoma. <i>PLoS ONE</i> , <b>2016</b> , 11, e0162502	3.7	14
180	Expressions of miR-30c and let-7a are inversely correlated with HMGA2 expression in squamous cell carcinoma of the vulva. <i>Oncotarget</i> , <b>2016</b> , 7, 85058-85062	3.3	13
179	Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells sensitivity to paclitaxel. <i>Oncotarget</i> , <b>2016</b> , 7, 12267-85	3.3	28
178	REG4 Is Highly Expressed in Mucinous Ovarian Cancer: A Potential Novel Serum Biomarker. <i>PLoS ONE</i> , <b>2016</b> , 11, e0151590	3.7	11
177	Cytogenetic and molecular profile of endometrial stromal sarcoma. <i>Genes Chromosomes and Cancer</i> , <b>2016</b> , 55, 834-46	5	39
176	BAG-1/SODD, HSP70, and HSP90 are potential prognostic markers of poor survival in node-negative breast carcinoma. <i>Human Pathology</i> , <b>2016</b> , 54, 64-73	3.7	10
175	MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma. <i>Human Pathology</i> , <b>2016</b> , 54, 74-81	3.7	8
174	MMP-7 is a highly specific negative marker for benign and malignant mesothelial cells in serous effusions. <i>Human Pathology</i> , <b>2016</b> , 47, 104-8	3.7	13
173	Progesterone Receptor Expression Is an Independent Prognosticator in FIGO Stage I Uterine Leiomyosarcoma. <i>American Journal of Clinical Pathology</i> , <b>2016</b> , 145, 449-58	1.9	18
172	Pre-analytical issues in effusion cytology. <i>Pleura and Peritoneum</i> , <b>2016</b> , 1, 45-56	2	19
171	L1CAM as a prognostic marker in stage I endometrial cancer: a validation study. <i>BMC Cancer</i> , <b>2016</b> , 16, 596	4.8	20
170	Ovarian Cancer Chemoresistance Relies on the Stem Cell Reprogramming Factor PBX1. <i>Cancer Research</i> , <b>2016</b> , 76, 6351-6361	10.1	45
169	Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules. <i>Cancer Cell</i> , <b>2015</b> , 28, 82-96	24.3	96
168	Protein expression of BIRC5, TK1, and TOP2A in malignant peripheral nerve sheath tumours--A prognostic test after surgical resection. <i>Molecular Oncology</i> , <b>2015</b> , 9, 1129-39	7.9	24
167	Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma. <i>Gynecologic Oncology</i> , <b>2015</b> , 139, 30-9	4.9	21
166	Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). <i>Modern Pathology</i> , <b>2015</b> , 28, 1101-22	9.8	107
165	Prognostic factors in malignant pleural mesothelioma. <i>Human Pathology</i> , <b>2015</b> , 46, 789-804	3.7	21
164	CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma. <i>Molecular Cancer</i> , <b>2015</b> , 14, 44	42.1	28

163	MicroRNAs in Ovarian Cancer. <i>Human Pathology</i> , <b>2015</b> , 46, 1245-56	3.7	51
162	The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions. <i>Human Pathology</i> , <b>2015</b> , 46, 1-8	3.7	42
161	HMGA2 expression pattern and TERT mutations in tumors of the vulva. <i>Oncology Reports</i> , <b>2015</b> , 33, 2675-80	3.9	13
160	Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma: Complementary Statement from the International Mesothelioma Interest Group, Also Endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology. <i>Diagnostic Cytopathology</i> , <b>2015</b> , 43, 563-76	1.4	25
159	Hsp70 (HSPA1) Lysine Methylation Status as a Potential Prognostic Factor in Metastatic High-Grade Serous Carcinoma. <i>PLoS ONE</i> , <b>2015</b> , 10, e0140168	3.7	12
158	Intra-Gene DNA Methylation Variability Is a Clinically Independent Prognostic Marker in Women's Cancers. <i>PLoS ONE</i> , <b>2015</b> , 10, e0143178	3.7	10
157	HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer. <i>Genome Medicine</i> , <b>2015</b> , 7, 108	14.4	110
156	Novel TNS3-MAP3K3 and ZFPM2-ELF5 fusion genes identified by RNA sequencing in multicystic mesothelioma with t(7;17)(p12;q23) and t(8;11)(q23;p13). <i>Cancer Letters</i> , <b>2015</b> , 357, 502-9	9.9	13
155	Guidelines for cytopathologic diagnosis of epithelioid and mixed type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology. <i>Cyto Journal</i> , <b>2015</b> , 12, 26	1.1	32
154	Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker. <i>BMC Cancer</i> , <b>2014</b> , 14, 80	4.8	80
153	Prognostic biomarkers in endometrial and ovarian carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2014</b> , 464, 315-31	5.1	35
152	The clinical and diagnostic role of microRNAs in ovarian carcinoma. <i>Gynecologic Oncology</i> , <b>2014</b> , 133, 640-6	4.9	37
151	Exosome-derived miRNAs and ovarian carcinoma progression. <i>Carcinogenesis</i> , <b>2014</b> , 35, 2113-20	4.6	104
150	Gene expression signatures of primary and metastatic uterine leiomyosarcoma. <i>Human Pathology</i> , <b>2014</b> , 45, 691-700	3.7	55
149	BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2014</b> , 464, 701-7	5.1	19
148	Ovarian cancer: diagnostic, biological and prognostic aspects. <i>Women's Health</i> , <b>2014</b> , 10, 519-33	3	62
147	The role of the tumor stroma in ovarian cancer. <i>Frontiers in Oncology</i> , <b>2014</b> , 4, 104	5.3	32
146	Low frequency of ESRRB-C11orf20 fusion gene in ovarian carcinomas. <i>PLoS Biology</i> , <b>2014</b> , 12, e1001784	9.7	11

145	Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions. <i>Gynecologic Oncology</i> , <b>2014</b> , 135, 118-24	4.9	41
144	Hepatocyte nuclear factor-1 $\beta$ s not a specific marker of clear cell carcinoma in serous effusions. <i>Cancer Cytopathology</i> , <b>2014</b> , 122, 153-8	3.9	3
143	APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival. <i>American Journal of Clinical Pathology</i> , <b>2014</b> , 142, 51-7	1.9	22
142	Mnk2 alternative splicing modulates the p38-MAPK pathway and impacts Ras-induced transformation. <i>Cell Reports</i> , <b>2014</b> , 7, 501-513	10.6	68
141	VICKZ2 protein expression in ovarian serous carcinoma effusions is associated with poor survival. <i>Human Pathology</i> , <b>2014</b> , 45, 1520-8	3.7	14
140	MEAF6/PHF1 is a recurrent gene fusion in endometrial stromal sarcoma. <i>Cancer Letters</i> , <b>2014</b> , 347, 75-8	9.9	68
139	AZGP1 and SPDEF mRNA expression differentiates breast carcinoma from ovarian serous carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2013</b> , 462, 163-73	5.1	7
138	Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion. <i>Human Pathology</i> , <b>2013</b> , 44, 2449-60	3.7	10
137	HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival. <i>Gynecologic Oncology</i> , <b>2013</b> , 129, 358-63	4.9	20
136	Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases. <i>Human Pathology</i> , <b>2013</b> , 44, 2677-83	3.7	24
135	Gene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcoma. <i>Gynecologic Oncology</i> , <b>2013</b> , 128, 349-55	4.9	34
134	Migfilin, $\beta$ parvin and $\gamma$ parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastases. <i>Gynecologic Oncology</i> , <b>2013</b> , 128, 364-70	4.9	4
133	Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance. <i>Human Pathology</i> , <b>2013</b> , 44, 777-85	3.7	16
132	Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma. <i>Human Pathology</i> , <b>2013</b> , 44, 1859-66	3.7	14
131	Alternatively spliced lysyl oxidase-like 4 isoforms have a pro-metastatic role in cancer. <i>Clinical and Experimental Metastasis</i> , <b>2013</b> , 30, 103-17	4.7	12
130	Fusion of the ZC3H7B and BCOR genes in endometrial stromal sarcomas carrying an X;22-translocation. <i>Genes Chromosomes and Cancer</i> , <b>2013</b> , 52, 610-8	5	81
129	Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. <i>EMBO Molecular Medicine</i> , <b>2013</b> , 5, 1051-66	12	178
128	Prognostic significance of residual tumor in patients with epithelial ovarian carcinoma stage IV in a 20 year perspective. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , <b>2012</b> , 91, 308-17	3.8	11



127	Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome. <i>Cancer</i> , <b>2012</b> , 118, 1543-53	6.4	17
126	Nucleoside transporters are widely expressed in ovarian carcinoma effusions. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2012</b> , 69, 467-75	3.5	15
125	MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival. <i>Gynecologic Oncology</i> , <b>2012</b> , 126, 460-5	4.9	17
124	Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 3197-206	12.9	41
123	Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions. <i>Human Pathology</i> , <b>2012</b> , 43, 529-35	3.7	18
122	Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival. <i>Human Pathology</i> , <b>2012</b> , 43, 496-505	3.7	23
121	SCARA3 mRNA is overexpressed in ovarian carcinoma compared with breast carcinoma effusions. <i>Human Pathology</i> , <b>2012</b> , 43, 669-74	3.7	22
120	Gene expression signatures differentiate adenocarcinoma of lung and breast origin in effusions. <i>Human Pathology</i> , <b>2012</b> , 43, 684-94	3.7	23
119	Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?. <i>European Journal of Cancer</i> , <b>2012</b> , 48, 2146-54	7.5	26
118	Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma. <i>Human Pathology</i> , <b>2012</b> , 43, 2062-9	3.7	61
117	Epithelial-mesenchymal transition in ovarian carcinoma. <i>Frontiers in Oncology</i> , <b>2012</b> , 2, 33	5.3	111
116	The diagnostic and research applications of flow cytometry in cytopathology. <i>Diagnostic Cytopathology</i> , <b>2012</b> , 40, 525-35	1.4	5
115	Ezrin and BCAR1/p130Cas mediate breast cancer growth as 3-D spheroids. <i>Clinical and Experimental Metastasis</i> , <b>2012</b> , 29, 527-40	4.7	13
114	Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2012</b> , 460, 193-202	5.1	11
113	HMG2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2012</b> , 460, 505-13	5.1	23
112	PRAME (preferentially expressed antigen of melanoma) is a novel marker for differentiating serous carcinoma from malignant mesothelioma. <i>American Journal of Clinical Pathology</i> , <b>2012</b> , 137, 240-7	1.9	9
111	Novel fusion of MYST/Esa1-associated factor 6 and PHF1 in endometrial stromal sarcoma. <i>PLoS ONE</i> , <b>2012</b> , 7, e39354	3.7	83
110	Breast Carcinoma <b>2012</b> , 69-77		1

109 Ovarian/Primary Peritoneal Carcinoma **2012**, 167-203

108 Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions. *Molecular Pharmaceutics*, **2011**, 8, 2080-8 5.6 28

107 Osteopontin expression in ovarian carcinoma effusions is related to improved clinical outcome. *Human Pathology*, **2011**, 42, 991-7 3.7 10

106 Class III  $\beta$ -tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance. *Human Pathology*, **2011**, 42, 1019-26 3.7 40

105 Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions. *Journal of Cellular and Molecular Medicine*, **2011**, 15, 535-44 5.6 41

104 miRNA profiling along tumour progression in ovarian carcinoma. *Journal of Cellular and Molecular Medicine*, **2011**, 15, 1593-602 5.6 96

103 Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status. *Tumor Biology*, **2011**, 32, 589-96 2.9 15

102 Netrin-4 is upregulated in breast carcinoma effusions compared to corresponding solid tumors. *Diagnostic Cytopathology*, **2011**, 39, 562-6 1.4 13

101 Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 18708-13 11.5 311

100 Expression and clinical role of protein of regenerating liver (PRL) phosphatases in ovarian carcinoma. *International Journal of Molecular Sciences*, **2011**, 12, 1133-45 6.3 16

99 Expression of Fatty Acid Synthase Depends on NAC1 and Is Associated with Recurrent Ovarian Serous Carcinomas. *Journal of Oncology*, **2010**, 2010, 285191 4.5 44

98 Breast carcinoma cells in primary tumors and effusions have different gene array profiles. *Journal of Oncology*, **2010**, 2010, 969084 4.5 16

97 Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma. *Human Pathology*, **2010**, 41, 794-804 3.7 40

96 Exploring the peritoneal surface malignancy phenotype--a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models. *Human Pathology*, **2010**, 41, 1109-19 3.7 20

95 Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. *American Journal of Pathology*, **2010**, 177, 1087-94 5.8 137

94 Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions. *Clinical and Experimental Metastasis*, **2010**, 27, 161-72 4.7 56

93 CD105 (Endoglin) expression in breast carcinoma effusions is a marker of poor survival. *Breast*, **2010**, 19, 493-8 3.6 20

92 Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions. *Journal of Cellular and Molecular Medicine*, **2010**, 15, 535-44 5.6 22

91	Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma. <i>PLoS ONE</i> , <b>2010</b> , 5, e11198	3.7	62
90	New determinates of disease progression and outcome in metastatic ovarian carcinoma. <i>Histology and Histopathology</i> , <b>2010</b> , 25, 1591-609	1.4	18
89	The anti-apoptotic activity of BAG3 is restricted by caspases and the proteasome. <i>PLoS ONE</i> , <b>2009</b> , 4, e5136	3.7	13
88	Pathogenesis of ovarian cancer: clues from selected overexpressed genes. <i>Future Oncology</i> , <b>2009</b> , 5, 1641-57	3.6	45
87	Different expression and clinical role of S100A4 in serous ovarian carcinoma at different anatomic sites. <i>Tumor Biology</i> , <b>2009</b> , 30, 15-25	2.9	19
86	Evaluation of cell surface expression of phosphatidylserine in ovarian carcinoma effusions using the annexin-V/7-AAD assay: clinical relevance and comparison with other apoptosis parameters. <i>American Journal of Clinical Pathology</i> , <b>2009</b> , 132, 756-62	1.9	32
85	Cell survival and apoptosis-related molecules in cancer cells in effusions: a comprehensive review. <i>Diagnostic Cytopathology</i> , <b>2009</b> , 37, 613-24	1.4	16
84	Lysyl oxidase-like 4 is alternatively spliced in an anatomic site-specific manner in tumors involving the serosal cavities. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2009</b> , 454, 71-9	5.1	19
83	Expression of the peroxisome proliferator-activated receptors-alpha, -beta, and -gamma in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival. <i>Human Pathology</i> , <b>2009</b> , 40, 705-13	3.7	18
82	Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions. <i>Human Pathology</i> , <b>2009</b> , 40, 527-37	3.7	19
81	Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian carcinoma. <i>Human Pathology</i> , <b>2009</b> , 40, 795-806	3.7	48
80	Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions. <i>Human Pathology</i> , <b>2009</b> , 40, 1453-60	3.7	59
79	Expression and clinical role of antiapoptotic proteins of the bag, heat shock, and Bcl-2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma. <i>International Journal of Gynecological Pathology</i> , <b>2009</b> , 28, 211-21	3.2	34
78	Tenascin-X is a novel diagnostic marker of malignant mesothelioma. <i>American Journal of Surgical Pathology</i> , <b>2009</b> , 33, 1673-82	6.7	54
77	Methods for simultaneous measurement of apoptosis and cell surface phenotype of epithelial cells in effusions by flow cytometry. <i>Nature Protocols</i> , <b>2008</b> , 3, 955-64	18.8	22
76	The chemokine receptor CXCR4 is more frequently expressed in breast compared to other metastatic adenocarcinomas in effusions. <i>Breast Journal</i> , <b>2008</b> , 14, 476-82	1.2	8
75	Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma. <i>Human Pathology</i> , <b>2008</b> , 39, 87-95	3.7	87
74	Claudin upregulation in ovarian carcinoma effusions is associated with poor survival. <i>Human Pathology</i> , <b>2008</b> , 39, 747-57	3.7	61

73	Different clinical roles for p21-activated kinase-1 in primary and recurrent ovarian carcinoma. <i>Human Pathology</i> , <b>2008</b> , 39, 1630-6	3.7	12
72	New diagnostic and molecular characteristics of malignant mesothelioma. <i>Ultrastructural Pathology</i> , <b>2008</b> , 32, 227-40	1.3	17
71	Small interfering RNA molecules targeting endothelin-converting enzyme-1 inhibit endothelin-1 synthesis and the invasive phenotype of ovarian carcinoma cells. <i>Cancer Research</i> , <b>2008</b> , 68, 9265-73	10.1	36
70	MicroRNA expression and identification of putative miRNA targets in ovarian cancer. <i>PLoS ONE</i> , <b>2008</b> , 3, e2436	3.7	273
69	Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma. <i>Cancer</i> , <b>2008</b> , 112, 84-93	6.4	36
68	Ovarian carcinoma cells in effusions show increased S-phase fraction compared to corresponding primary tumors. <i>Diagnostic Cytopathology</i> , <b>2008</b> , 36, 637-44	1.4	7
67	Assessment of endoglin and calprotectin as potential biomarkers in ovarian carcinoma and borderline tumors of the ovary. <i>American Journal of Obstetrics and Gynecology</i> , <b>2008</b> , 199, 533.e1-8	6.4	13
66	Flow cytometric immunphenotyping of epithelial cancer cells in effusions--technical considerations and pitfalls. <i>Cytometry Part B - Clinical Cytometry</i> , <b>2007</b> , 72, 332-43	3.4	23
65	Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma. <i>Cancer</i> , <b>2007</b> , 109, 228-38	6.4	58
64	Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma. <i>Cancer</i> , <b>2007</b> , 110, 1264-71	6.4	38
63	Heparanase expression correlates with poor survival in metastatic ovarian carcinoma. <i>Gynecologic Oncology</i> , <b>2007</b> , 104, 311-9	4.9	36
62	Flow cytometric immunophenotyping of cancer cells in effusion specimens: diagnostic and research applications. <i>Diagnostic Cytopathology</i> , <b>2007</b> , 35, 568-78	1.4	18
61	MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells. <i>Diagnostic Cytopathology</i> , <b>2007</b> , 35, 756-60	1.4	39
60	The diagnostic role of claudins in serous effusions. <i>American Journal of Clinical Pathology</i> , <b>2007</b> , 127, 928-37	1.9	37
59	BAG-4/SODD and associated antiapoptotic proteins are linked to aggressiveness of epithelial ovarian cancer. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 6585-92	12.9	30
58	Anatomic site-related expression of cancer-associated molecules in ovarian carcinoma. <i>Current Cancer Drug Targets</i> , <b>2007</b> , 7, 109-20	2.8	17
57	Chemokine receptors are infrequently expressed in malignant and benign mesothelial cells. <i>American Journal of Clinical Pathology</i> , <b>2007</b> , 127, 752-9	1.9	15
56	Survivin, a member of the inhibitors of apoptosis family, is down-regulated in breast carcinoma effusions. <i>American Journal of Clinical Pathology</i> , <b>2007</b> , 128, 389-97	1.9	15

55	Expression and clinical role of the bric-a-brac tramtrack broad complex/poxvirus and zinc protein NAC-1 in ovarian carcinoma effusions. <i>Human Pathology</i> , <b>2007</b> , 38, 1030-1036	3.7	27
54	Expression of inhibitor-of-apoptosis protein family members in malignant mesothelioma. <i>Human Pathology</i> , <b>2007</b> , 38, 986-994	3.7	53
53	Biological characteristics of cancers involving the serosal cavities. <i>Critical Reviews in Oncogenesis</i> , <b>2007</b> , 13, 189-227	1.3	37
52	The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinoma. <i>Gynecologic Oncology</i> , <b>2006</b> , 100, 462-8	4.9	19
51	The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma. <i>Gynecologic Oncology</i> , <b>2006</b> , 102, 453-61	4.9	69
50	Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival. <i>Gynecologic Oncology</i> , <b>2006</b> , 103, 814-9	4.9	39
49	The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma. <i>Gynecologic Oncology</i> , <b>2006</b> , 103, 831-40	4.9	27
48	Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 791-9	12.9	68
47	Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 5944-50	12.9	89
46	A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2006</b> , 103, 18739-44	11.5	104
45	NK- and B-Cell Infiltration Correlates With Worse Outcome in Metastatic Ovarian Carcinoma. <i>American Journal of Clinical Pathology</i> , <b>2006</b> , 125, 451-458	1.9	122
44	The biological differences between ovarian serous carcinoma and diffuse peritoneal malignant mesothelioma. <i>Seminars in Diagnostic Pathology</i> , <b>2006</b> , 23, 35-43	4.3	12
43	Cadherin expression in ovarian carcinoma and malignant mesothelioma cell effusions. <i>Acta Cytologica</i> , <b>2006</b> , 50, 603-7	3	28
42	D2-40 is not a specific marker for cells of mesothelial origin in serous effusions. <i>American Journal of Surgical Pathology</i> , <b>2006</b> , 30, 878-82	6.7	42
41	Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2006</b> , 449, 31-9	5.1	73
40	Expression of E-cadherin transcriptional regulators in ovarian carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2006</b> , 449, 520-8	5.1	92
39	Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients. <i>Molecular Cancer</i> , <b>2005</b> , 4, 26	42.1	22
38	Site-related expression of metastasis-associated and signaling molecules in malignant mesothelioma--a new model for the study of tumor biology and disease progression. <i>Lung Cancer</i> , <b>2005</b> , 49 Suppl 1, S89-93	5.9	2

37	HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. <i>Gynecologic Oncology</i> , <b>2005</b> , 96, 42-7	4.9	83
36	Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. <i>Cancer</i> , <b>2005</b> , 103, 1631-43	6.4	319
35	Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma. <i>Cancer</i> , <b>2005</b> , 103, 2313-9	6.4	28
34	Quantitative analysis of integrin expression in effusions using flow cytometric immunophenotyping. <i>Diagnostic Cytopathology</i> , <b>2005</b> , 33, 325-31	1.4	20
33	Angiogenic molecule expression is downregulated in effusions from breast cancer patients. <i>Breast Cancer Research and Treatment</i> , <b>2005</b> , 94, 71-80	4.4	21
32	Kallikrein 4 Expression Is Up-Regulated in Epithelial Ovarian Carcinoma Cells in Effusions. <i>American Journal of Clinical Pathology</i> , <b>2005</b> , 123, 360-368	1.9	20
31	Apolipoprotein E is required for cell proliferation and survival in ovarian cancer. <i>Cancer Research</i> , <b>2005</b> , 65, 331-7	10.1	94
30	Laminin-induced signaling in tumor cells: the role of the M(r) 67,000 laminin receptor. <i>Cancer Research</i> , <b>2004</b> , 64, 3572-9	10.1	113
29	Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 7335-46	12.9	60
28	Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma. <i>Breast Cancer Research and Treatment</i> , <b>2004</b> , 83, 119-28	4.4	73
27	The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions. <i>Clinical and Experimental Metastasis</i> , <b>2004</b> , 21, 191-9	4.7	23
26	Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma. <i>Clinical and Experimental Metastasis</i> , <b>2004</b> , 21, 469-76	4.7	31
25	Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma. <i>Cancer</i> , <b>2004</b> , 100, 2139-47	6.4	83
24	Malignant effusions: from diagnosis to biology. <i>Diagnostic Cytopathology</i> , <b>2004</b> , 31, 246-54	1.4	68
23	Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma. <i>Lung Cancer</i> , <b>2004</b> , 44, 159-65	5.9	38
22	Expression of the 67 kDa laminin receptor and the alpha6 integrin subunit in serous ovarian carcinoma. <i>Clinical and Experimental Metastasis</i> , <b>2003</b> , 20, 599-609	4.7	20
21	Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma. <i>Clinical and Experimental Metastasis</i> , <b>2003</b> , 20, 621-31	4.7	57
20	Coordinated expression of integrin subunits, matrix metalloproteinases (MMP), angiogenic genes and Ets transcription factors in advanced-stage ovarian carcinoma: a possible activation pathway?. <i>Cancer and Metastasis Reviews</i> , <b>2003</b> , 22, 103-15	9.6	44

19	EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. <i>Clinical and Experimental Metastasis</i> , <b>2003</b> , 20, 161-9	4.7	111
18	AlphaV- and beta1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients. <i>Gynecologic Oncology</i> , <b>2003</b> , 90, 248-57	4.9	68
17	Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions. <i>Gynecologic Oncology</i> , <b>2003</b> , 91, 160-72	4.9	53
16	Effusion cytology in ovarian cancer: new molecular methods as aids to diagnosis and prognosis. <i>Clinics in Laboratory Medicine</i> , <b>2003</b> , 23, 729-54, viii	2.1	42
15	PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 1412-9	12.9	36
14	Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 2248-59	12.9	76
13	Caveolin-1 expression in ovarian carcinoma is MDR1 independent. <i>American Journal of Clinical Pathology</i> , <b>2002</b> , 117, 225-34	1.9	25
12	Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions. <i>Clinical and Experimental Metastasis</i> , <b>2002</b> , 19, 135-44	4.7	34
11	Detection of malignant epithelial cells in effusions using flow cytometric immunophenotyping: an analysis of 92 cases. <i>American Journal of Clinical Pathology</i> , <b>2002</b> , 118, 85-92	1.9	46
10	The biological role and regulation of matrix metalloproteinases (MMP) in cancer. <i>Arkhiv Patologii</i> , <b>2002</b> , 64, 47-53	0.2	20
9	Infertility treatment after conservative management of borderline ovarian tumors. <i>Cancer</i> , <b>2001</b> , 92, 320-5	6.4	53
8	Detection of monocyte/macrophage cell populations in effusions: a comparative study using flow cytometric immunophenotyping and immunocytochemistry. <i>Diagnostic Cytopathology</i> , <b>2001</b> , 25, 214-9	1.4	20
7	Ovarian carcinoma and serous effusions. Changing views regarding tumor progression and review of current literature. <i>Analytical Cellular Pathology</i> , <b>2001</b> , 23, 107-28		31
6	Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome. <i>American Journal of Surgical Pathology</i> , <b>2001</b> , 25, 1493-500	6.7	36
5	The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells. <i>American Journal of Surgical Pathology</i> , <b>2001</b> , 25, 1405-12	6.7	155
4	E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions. <i>Journal of Pathology</i> , <b>2000</b> , 192, 460-9	9.4	93
3	Expression of CD44 in effusions of patients diagnosed with serous ovarian carcinoma--diagnostic and prognostic implications. <i>Clinical and Experimental Metastasis</i> , <b>2000</b> , 18, 197-202	4.7	33
2	High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. <i>Clinical and Experimental Metastasis</i> , <b>1999</b> , 17, 799-808	4.7	130

1 Molecular Genetics of Uterine Sarcomas 1-7